Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 2OTHER_GOV 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 11Gastrointestinal 9Genitourinary 8Breast 8CNS 5Tumor-Agnostic 4Thoracic 4Sarcoma 3Myeloid 3Endocrine 3Lymphoid 2Other solid neoplasm 1Other hematologic neoplasm 1NET 1

Conditions

Neuroendocrine Tumors 1Carcinoid Tumor 1

Interventions

lutetium Lu 177 dotatate 7Specimen Handling 7Magnetic Resonance Spectroscopy 7gallium Ga 68 dotatate 3cabozantinib 3X-Rays 3Everolimus 3Sunitinib 2Phantoms, Imaging 23-aminopyridine-2-carboxaldehyde thiosemicarbazone 2romidepsin 1peposertib 1pembrolizumab 1pazopanib 1olaparib 1fludarabine 1belinostat 1aldesleukin 1Sorafenib 1Salts 1Photons 1Octreotide 1Nivolumab 1Lactones 1Ipilimumab 1Introns 1Interferon alpha-2 1Immunoglobulin G 1Fluorodeoxyglucose F18 1Etoposide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × olaparib × NET × Clear all
NCT04086485 2026-05-22

Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)

National Institutes of Health Clinical Center (CC)

Phase 1/2 Recruiting
56 enrolled
EndocrineNET

Carcinoid Tumor, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡